Form 8-K Aurinia Pharmaceuticals For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
June 30, 2025 1:10 PM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $10.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH).
The analyst comments "First-in-human (FIH) data with aritinercept (AUR200) appear competitive with the many other APRIL/ BAFF assets in development; however, we await the initiation of clinical studies in autoimmune diseases in 2H25 for a better understanding of its potential place in the treatment class. This morning, Aurinia (AUPH, OP) disclosed Ph.1 single ascending dose... More
